File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Closeout of the HALT-PKD trials

TitleCloseout of the HALT-PKD trials
Authors
KeywordsCloseout
Data coordination
Patient safety
Regulatory
Unblinding
Issue Date2015
Citation
Contemporary Clinical Trials, 2015, v. 44, p. 48-55 How to Cite?
AbstractBackground: The HALT Polycystic Kidney Disease Trials Network consisted of two randomized, double blind, placebo-controlled trials among patients with autosomal dominant polycystic kidney disease. The trials involved 5-8. years of participant follow-up with interventions in blood pressure and antihypertensive therapy. We provide a framework for designing and implementing closeout near the end of a trial while ensuring patient safety and maintaining scientific rigor and study morale. Methods: We discuss issues and resolutions for determining the last visit, tapering medications, and unblinding of participants to study allocation and results. We also discuss closure of clinical sites and Data Coordinating Center responsibilities to ensure timely release of study results and meeting the requirements of regulatory and funding authorities. Results: Just over 90% of full participants had a 6-month study visit prior to their last visit preparing them for trial closeout. Nearly all patients wanted notification of study results (99%) and treatment allocation (99%). All participants were safely tapered off study and open label blood pressure medications. Within 6. months, the trials were closed, primary papers published, and 805 letters distributed to participants with results and allocation. DCC obligations for data repository and clinicaltrials.gov reporting were completed within 12. months of the last study visit. Conclusions: Closeout of our trials involved years of planning and significant human and financial resources. We provide questions for investigators to consider when planning closeout of their trials with focus on (1) patient safety, (2) dissemination of study results and (3) compliance with regulatory and funding responsibilities.
Persistent Identifierhttp://hdl.handle.net/10722/316111
ISSN
2023 Impact Factor: 2.0
2023 SCImago Journal Rankings: 0.980
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMoore, Charity G.-
dc.contributor.authorSpillane, Susan-
dc.contributor.authorSimon, Gertrude-
dc.contributor.authorMaxwell, Barbara-
dc.contributor.authorRahbari-Oskoui, Frederic F.-
dc.contributor.authorBraun, William E.-
dc.contributor.authorChapman, Arlene B.-
dc.contributor.authorSchrier, Robert W.-
dc.contributor.authorTorres, Vicente E.-
dc.contributor.authorPerrone, Ronald D.-
dc.contributor.authorSteinman, Theodore I.-
dc.contributor.authorBrosnahan, Godela-
dc.contributor.authorCzarnecki, Peter G.-
dc.contributor.authorHarris, Peter C.-
dc.contributor.authorMiskulin, Dana C.-
dc.contributor.authorFlessner, Michael F.-
dc.contributor.authorBae, K. Ty-
dc.contributor.authorAbebe, Kaleab Z.-
dc.contributor.authorHogan, Marie C.-
dc.date.accessioned2022-08-24T15:49:17Z-
dc.date.available2022-08-24T15:49:17Z-
dc.date.issued2015-
dc.identifier.citationContemporary Clinical Trials, 2015, v. 44, p. 48-55-
dc.identifier.issn1551-7144-
dc.identifier.urihttp://hdl.handle.net/10722/316111-
dc.description.abstractBackground: The HALT Polycystic Kidney Disease Trials Network consisted of two randomized, double blind, placebo-controlled trials among patients with autosomal dominant polycystic kidney disease. The trials involved 5-8. years of participant follow-up with interventions in blood pressure and antihypertensive therapy. We provide a framework for designing and implementing closeout near the end of a trial while ensuring patient safety and maintaining scientific rigor and study morale. Methods: We discuss issues and resolutions for determining the last visit, tapering medications, and unblinding of participants to study allocation and results. We also discuss closure of clinical sites and Data Coordinating Center responsibilities to ensure timely release of study results and meeting the requirements of regulatory and funding authorities. Results: Just over 90% of full participants had a 6-month study visit prior to their last visit preparing them for trial closeout. Nearly all patients wanted notification of study results (99%) and treatment allocation (99%). All participants were safely tapered off study and open label blood pressure medications. Within 6. months, the trials were closed, primary papers published, and 805 letters distributed to participants with results and allocation. DCC obligations for data repository and clinicaltrials.gov reporting were completed within 12. months of the last study visit. Conclusions: Closeout of our trials involved years of planning and significant human and financial resources. We provide questions for investigators to consider when planning closeout of their trials with focus on (1) patient safety, (2) dissemination of study results and (3) compliance with regulatory and funding responsibilities.-
dc.languageeng-
dc.relation.ispartofContemporary Clinical Trials-
dc.subjectCloseout-
dc.subjectData coordination-
dc.subjectPatient safety-
dc.subjectRegulatory-
dc.subjectUnblinding-
dc.titleCloseout of the HALT-PKD trials-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cct.2015.07.017-
dc.identifier.scopuseid_2-s2.0-84938389826-
dc.identifier.volume44-
dc.identifier.spage48-
dc.identifier.epage55-
dc.identifier.eissn1559-2030-
dc.identifier.isiWOS:000362616300008-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats